Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000965416 | SCV001112683 | benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002503030 | SCV002805258 | likely benign | Age related macular degeneration 9; Atypical hemolytic-uremic syndrome with C3 anomaly; Complement component 3 deficiency | 2021-09-16 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526052 | SCV005040399 | likely benign | not specified | 2024-03-05 | criteria provided, single submitter | clinical testing | Variant summary: C3 c.1344C>T alters a conserved nucleotide resulting in a synonymous change. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0003 in 251358 control chromosomes, predominantly at a frequency of 0.0035 within the African or African-American subpopulation in the gnomAD database. To our knowledge, no occurrence of c.1344C>T in individuals affected with C3 related diseases and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 783814). Based on the evidence outlined above, the variant was classified as likely benign. |
Breakthrough Genomics, |
RCV000965416 | SCV005312461 | benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003916184 | SCV004731480 | likely benign | C3-related disorder | 2019-05-23 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |